2-chloro-5-nitro-N-phenylbenzamide

• ChemBase编号: 5496
• 分子式: C13H9ClN2O3
• 平均质量: 276.67516
• 单一同位素质量: 276.03016984
• SMILES: Clc1ccc([N+](=O)[O-])cc1C(=O)Nc1ccccc1
• Canonical SMILES: Clc1ccc(cc1C(=O)Nc1ccccc1)[N+](=O)[O-]
• InChI: InChI=1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)
• InChIKey: DNTSIBUQMRRYIU-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-chloro-5-nitro-N-phenylbenzamide
• IUPAC传统名: 2-chloro-5-nitrobenzanilide
• 别名: 2-氯-5-硝基-N-苯基苯酰胺; GW9662; 2-Chloro-5-nitro-N-4-phenylbenzamide; 2-chloro-5-nitro-N-phenylbenzamide; 2-Chloro-5-nitro-N-phenylbenzamide; GW9662; GW9662; 2-Chloro-5-nitrobenzanilide

登记号

• CAS号: 22978-25-2
• MDL号: MFCD01215270
• PubChem SID: 24883187; 24278560; 99444334; 160968924
• PubChem CID: 644213

理论计算性质

JChem

• Acid pKa: 11.418081
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 3.609159
• LogD (pH = 7.4): 3.60912
• Log P: 3.6091595
• 摩尔折射率: 72.7168 cm^3
• 极化性: 26.737232 Å^3
• 极化表面积: 72.24 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 3.39
• LOG S: -4.74
• 溶解度: 5.01e-03 g/l

分子性质

理化性质

• 溶解度: DMSO; DMSO: soluble26 mg/mL; H2O: insoluble
• 外观: Off-White Solid; white powder
• 熔点: 158-159 °C(lit.)

安全信息

• 欧盟危险性物质标志: 刺激性(Irritant) (Xi)
• 德国WGK号: 3
• 危险公开号: 36-43
• 安全公开号: 26-36/37
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H317-H319
• GHS警示性声明: P280-P305 + P351 + P338
• 保存温度: 2-8°C

药理学性质

• 作用靶点: PPAR
• 相关基因信息: human ... PPARG(5468)

产品相关信息

• 纯度: >98% (HPLC); 97%
• 成盐信息: Free Base
• 线性分子式: ClC6H3(NO2)CONHC6H5
• Empirical Formula (Hill Notation): C13H9ClN2O3

详细说明

DrugBank - DB07863

Drug information: experimental

Sigma Aldrich - M6191

Legal Information
Sold for research purposes only, under agreement from Glaxo-Smith-Kline
Biochem/physiol Actions
GW9662 is an irreversible PPARγ antagonist. GW9662 inhibits connective tissue growth factor and activation of CD36 by IL-4.

Sigma Aldrich - 642355

包装
25 g in glass bottle

Toronto Research Chemicals - C374050

A cell-permeable, selective and irreversible PPARγ antagonist (IC50 = 3.3 nM, 32 nM, and 2 μM for PPARγ, PPARα, and PPARδ, respectively). Reported to covalently modify a cysteine residue in the binding site of PPAR. At a concentration of 10 μM, also acts as an agonist of human pregnane X receptor (PXR) and farnesoid X receptor (FXR). Does not activate liver X receptor-a (LXRa), retinoic acid receptor (RAR), retinoid X receptor-a (RXRa) and thyroid receptors a and b (TRa and TRb)

参考文献

• Huang, J.T., et al.: Nature, 400, 378 (1999)
• Wilson, T.M., et al.: J. Med. Chem., 43, 527 (1999)
• Leesnitzer, L.M., et al.: Biochemistry, 41, 6640 (2002)